Pirfenidone - represents an appropriate treatment option for patients with idiopathic pulmonary fibrosis

Pirfenidone Phase 3 Results Published Today in The Lancet. InterMune, Inc. (Nasdaq: ITMN) today announced the publication of results from two Phase 3 trials demonstrating that treatment with pirfenidone, a novel antifibrotic and anti-inflammatory drug, was associated with favorable effects on lung function, 6-minute walk test distance and progression-free survival (PFS) in patients with mild to moderate idiopathic pulmonary fibrosis (IPF).

Read story here
www.prnewswire.com/news-releases/pirfenidone-phase-3-results-published-today-in-the-lancet-121811908.html